CoChat
Sign Up
Cited by 969

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Clinical relevance of circulating cell-free microRNAs in cancer

Schwarzenbach, Heidi, Nishida, Naohiro, Calin, George A., Pantel, Klaus·2014·Nature Reviews Clinical Oncology
DOI 10.1038/nrclinonc.2014.5
Open this paper in CoChat — free account

Abstract

Efficient patient management relies on early diagnosis of disease and monitoring of treatment. In this regard, much effort has been made to find informative, blood-based biomarkers for patients with cancer. Owing to their attributes-which are specifically modulated by the tumour-circulating cell-free microRNAs found in the peripheral blood of patients with cancer may provide insights into the biology of the tumour and the effects of therapeutic interventions. Moreover, the role of microRNAs in the regulation of different cellular processes points to their clinical utility as blood-based biomarkers and future therapeutic targets. MicroRNAs are optimal biomarkers owing to high stability under storage and handling conditions and their presence in blood, urine and other body fluids. In particular, detection of levels of microRNAs in blood plasma and serum has the potential for an earlier cancer diagnosis and to predict prognosis and response to therapy. This Review article considers the latest developments in the use of circulating microRNAs as prognostic and predictive biomarkers and discusses their utility in personalized medicine.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2014.5

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 125

  1. Pritchard, C. C., Cheng, H. H. & Tewari, M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13, 358–369 (2012). · DOI · Paper page
  2. Cortez, M. A. et al. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8, 467–477 (2011). · DOI
  3. Turchinovich, A., Weiz, L. & Burwinkel, B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem. Sci. 37, 460–465 (2012). · DOI
  4. Kim, V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376–385 (2005). · DOI · Paper page
  5. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009). · DOI · Paper page
  6. Höck, J. & Meister, G. The Argonaute protein family. Genome Biol. 9, 210 (2008). · DOI
  7. Portnoy, V., Huang, V., Place, R. F. & Li, L. C. Small RNA and transcriptional upregulation. Wiley Interdiscip. Rev. RNA 2, 748–760 (2011). · DOI
  8. Place, R. F., Li, L. C., Pookot, D., Noonan, E. J. & Dahiya, R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl Acad. Sci. USA 105, 1608–1613 (2008). · DOI
  9. Vasudevan, S., Tong, Y. & Steitz, J. A. Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 1931–1934 (2007). · DOI
  10. Suzuki, H. I. & Miyazono, K. Emerging complexity of microRNA generation cascades. J. Biochem. 149, 15–25 (2011). · DOI
  11. Suzuki, H. I. et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44, 424–436 (2011). · DOI
  12. Esquela-Kerscher, A. & Slack, F. J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–269 (2006). · DOI
  13. Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J. & Kerin, M. J. MicroRNAs as novel biomarkers for breast cancer. J. Oncol. 2009, 950201 (2009).
  14. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A. & Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313, 139–142 (2001). · DOI
  15. Okada, H., Kohanbash, G. & Lotze, M. T. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int. J. Biochem. Cell Biol. 42, 1256–1261 (2010). · DOI
  16. Ha, T. Y. The role of microRNAs in regulatory T cells and in the immune response. Immune Netw. 11, 11–41 (2011). · DOI
  17. Toffanin, S., Sia, D. & Villanueva, A. microRNAs: new ways to block tumor angiogenesis? J. Hepatol. 57, 490–491 (2012). · DOI
  18. Pegtel, D. M. et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA 107, 6328–6333 (2010). · DOI
  19. Vickers, K. C. & Remaley, A. T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23, 91–97 (2012). · DOI · Paper page
  20. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476 (2008). · DOI · Paper page
  21. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005). · DOI
  22. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257–2261 (2006). · DOI · Paper page
  23. Yu, S. L. et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13, 48–57 (2008). · DOI
  24. Dvinge, H. et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378–382 (2013). · DOI
  25. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008). · DOI · Paper page
  26. Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003–5008 (2011). · DOI · Paper page
  27. Kroh, E. M., Parkin, R. K., Mitchell, P. S. & Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50, 298–301 (2010). · DOI
  28. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223–7233 (2011). · DOI · Paper page
  29. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005). · DOI
  30. Castoldi, M. et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA 12, 913–920 (2006). · DOI
  31. Shendure, J. & Ji, H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135–1145 (2008). · DOI · Paper page
  32. Ryan, B. M., Robles, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 10, 389–402 (2010). · DOI
  33. Chang, H. T. et al. Comprehensive analysis of microRNAs in breast cancer. BMC Genomics 13 (Suppl. 7), S18 (2012). · DOI
  34. Li, S. C. et al. miRNA arm selection and isomiR distribution in gastric cancer. BMC Genomics 13 (Suppl. 1), S13 (2012). · DOI · Paper page
  35. Williams, Z. et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc. Natl Acad. Sci. USA 110, 4255–4260 (2013). · DOI
  36. Hafner, M. et al. RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. RNA 17, 1697–1712 (2011). · DOI · Paper page
  37. Lawrie, C. H. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141, 672–675 (2008). · DOI
  38. Shen, J. et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11, 374 (2011). · DOI
  39. Roth, C., Kasimir-Bauer, S., Pantel, K. & Schwarzenbach, H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 5, 281–291 (2011). · DOI
  40. Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7, e38248 (2012). · DOI
  41. Cui, E. H. et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol. Sin. 34, 309–313 (2013). · DOI
  42. Wang, Y. et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73, 4801–4809 (2013). · DOI
  43. Hu, Z. et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721–1726 (2010). · DOI · Paper page
  44. Yuxia, M., Zhennan, T. & Wei, Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J. Cancer Res. Clin. Oncol. 138, 2045–2050 (2012). · DOI
  45. Huang, Y. et al. MicroRNA-21 gene and cancer. Med. Oncol. 30, 376 (2013). · DOI
  46. Liu, X. G. et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 29, 618–626 (2012). · DOI
  47. Sanfiorenzo, C. et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE 8, e54596 (2013). · DOI
  48. Pepek, J. M. et al. How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: a comparison of the TNM 6 and 7 systems. J. Thorac. Oncol. 6, 757–761 (2011). · DOI
  49. Kaduthanam, S. et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80, 223–227 (2013). · DOI
  50. Silva, J. et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J. 37, 617–623 (2011). · DOI
  51. Wang, T. et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE 7, e43268 (2012). · DOI
  52. Chen, W., Cai, F., Zhang, B., Barekati, Z. & Zhong, X. Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 34, 455–462 (2013). · DOI
  53. Wang, F., Zheng, Z., Guo, J. & Ding, X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119, 586–593 (2010). · DOI
  54. Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12, R90 (2010). · DOI
  55. Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V. & Pantel, K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 134, 933–941 (2012). · DOI
  56. Asaga, S. et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57, 84–91 (2011). · DOI
  57. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011). · DOI
  58. Gorges, T. M. & Pantel, K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol. Immunother. 62, 931–939 (2013). · DOI
  59. Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573–581 (2013). · DOI
  60. Zhang, L. et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 18, 5701–5710 (2012). · DOI
  61. Madhavan, D. et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18, 5972–5982 (2012). · DOI
  62. Roth, C., Kasimir-Bauer, S., Heubner, M., Pantel, K. & Schwarzenbach, H. in Circulating nucleic acids in plasma and serum (ed. Gahan, P. B.) 63–71 (Springer, 2011).
  63. Hong, F., Li, Y., Xu, Y. & Zhu, L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J. Int. Med. Res. 41, 64–71 (2013). · DOI
  64. Xu, Y. Z., Xi, Q. H., Ge, W. L. & Zhang, X. Q. Identification of serum MicroRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14, 1057–1060 (2013). · DOI
  65. Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 138, 671–674 (2012). · DOI
  66. Chen, J. et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 32, 557–567 (2013). · DOI
  67. Zhao, S., Yao, D., Chen, J. & Ding, N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet. Test. Mol. Biomarkers 17, 631–636 (2013).
  68. Yaman Agaoglu, F. et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32, 583–588 (2011). · DOI
  69. Nguyen, H. C. et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73, 346–354 (2012).
  70. Zhang, H. L. et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326–331 (2011). · DOI
  71. Shen, J. et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72, 1469–1477 (2012). · DOI
  72. Brase, J. C. et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128, 608–616 (2011). · DOI
  73. Selth, L. A. et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br. J. Cancer 109, 641–650 (2013). · DOI
  74. Bryant, R. J. et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106, 768–774 (2012). · DOI
  75. Shah, M. A. & Kurtz, R. C. Upper gastrointestinal cancer predisposition syndromes. Hematol. Oncol. Clin. North Am. 24, 815–835 (2010). · DOI
  76. Han, M. et al. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol. Cell Biochem. 363, 427–436 (2012). · DOI
  77. Komatsu, S. et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 105, 104–111 (2011). · DOI
  78. Takeshita, N. et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br. J. Cancer 108, 644–652 (2013). · DOI
  79. Liu, R. et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J. Toxicol. Environ. Health A 75, 1154–1162 (2012). · DOI
  80. Cheng, H. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6, e17745 (2011). · DOI
  81. Wang, L. G. & Gu, J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 36, e61–e67 (2012). · DOI
  82. Kuo, T. Y. et al. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS ONE 7, e31587 (2012). · DOI
  83. Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375–1381 (2009). · DOI · Paper page
  84. Tsai, K. W. et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 51, 394–401 (2012). · DOI · Paper page
  85. Valladares-Ayerbes, M. et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med. 10, 186 (2012). · DOI
  86. Komatsu, S. et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33, 271–276 (2013).
  87. Zhou, H. et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl.) 88, 709–717 (2010). · DOI
  88. Yamamoto, Y. et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14, 529–538 (2009). · DOI
  89. Zhou, J. et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 29, 4781–4788 (2011). · DOI
  90. Koberle, V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur. J. Cancer 49, 3442–3449 (2013). · DOI
  91. Tomimaru, Y. et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 56, 167–175 (2012). · DOI
  92. Liu, J. et al. Combination of plasma microRNAs with serum CA19–19 for early detection of pancreatic cancer. Int. J. Cancer 131, 683–691 (2012). · DOI
  93. Liu, R. et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 58, 610–618 (2012). · DOI
  94. Hanash, S. M., Baik, C. S. & Kallioniemi, O. Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142–150 (2011). · DOI
  95. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008). · DOI
  96. Chim, S. S. et al. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 54, 482–490 (2008). · DOI
  97. Le, H. B. et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med. Oncol. 29, 3190–3197 (2012). · DOI
  98. Jung, E. J. et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118, 2603–2614 (2012). · DOI
  99. Zheng, D. et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4, 575–586 (2011).
  100. Sun, Y. et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE 7, e47003 (2012). · DOI
  101. Ohyashiki, K. et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS ONE 6, e16408 (2011). · DOI
  102. Wei, J. et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 30, 407–414 (2011). · DOI
  103. Kurashige, J. et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J. Surg. Oncol. 106, 188–192 (2012). · DOI
  104. Wang, P. et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol. Oncol. 7, 334–345 (2013). · DOI
  105. Zhou, M. et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 285, 21496–21507 (2010). · DOI
  106. Wang, H. et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 7, e34210 (2012). · DOI
  107. Lee, L. W. et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16, 2170–2180 (2010). · DOI
  108. Madhavan, D., Cuk, K., Burwinkel, B. & Yang, R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet. 4, 116 (2013).
  109. Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–789 (2010). · DOI
  110. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013). · DOI
  111. Fabbri, M. et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl Acad. Sci. USA 109, E2110–E2116 (2012). · DOI · Paper page
  112. Chen, X. et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 130, 1620–1628 (2012). · DOI
  113. Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 138, 671–674 (2012). · DOI
  114. Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 10, 55 (2012). · DOI
  115. Wang, S. et al. A plasma microRNA panel for early detection of colorectal cancer. Int. J. Cancer http://dx.doi.org/10.1002/ijc.28136 (2013). · DOI
  116. Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47, 784–791 (2011). · DOI
  117. Zhang, C. et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin. Chem. 56, 1871–1879 (2010). · DOI
  118. Hsu, C. M. et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol. 33, 1933–1942 (2012). · DOI
  119. Yu, S. et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97, 2084–2092 (2012). · DOI
  120. Yang, C. et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int. J. Cancer 132, 116–127 (2013). · DOI
  121. Kanemaru, H. et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 61, 187–193 (2011). · DOI
  122. Zuo, Z. et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 118, 413–415 (2011). · DOI
  123. Guo, H. Q., Huang, G. L., Guo, C. C., Pu, X. X. & Lin, T. Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis. Markers 29, 251–258 (2010). · DOI
  124. Ferrajoli, A. et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122, 1891–1899 (2013). · DOI
  125. Tanaka, K. et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal Cancer. Ann. Surg. Oncol. 20 (Suppl. 3), 670–615 (2013).

Cited by

Sorted by citations

Metadata

Authors
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K.
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2014-02-04
Volume
11
Issue
3
Pages
145-156
ISSN
  • 1759-4774
  • 1759-4782
DOI
10.1038/nrclinonc.2014.5
Cited by
969
References
5
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review